GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » ROE %

Heidelberg Pharma AG (XTER:HPHA) ROE % : -38.06% (As of Feb. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Heidelberg Pharma AG's annualized net income for the quarter that ended in Feb. 2024 was €-17.98 Mil. Heidelberg Pharma AG's average Total Stockholders Equity over the quarter that ended in Feb. 2024 was €47.23 Mil. Therefore, Heidelberg Pharma AG's annualized ROE % for the quarter that ended in Feb. 2024 was -38.06%.

The historical rank and industry rank for Heidelberg Pharma AG's ROE % or its related term are showing as below:

XTER:HPHA' s ROE % Range Over the Past 10 Years
Min: -267.02   Med: -50.93   Max: -35.08
Current: -35.56

During the past 13 years, Heidelberg Pharma AG's highest ROE % was -35.08%. The lowest was -267.02%. And the median was -50.93%.

XTER:HPHA's ROE % is ranked better than
54.34% of 1360 companies
in the Biotechnology industry
Industry Median: -43.445 vs XTER:HPHA: -35.56

Heidelberg Pharma AG ROE % Historical Data

The historical data trend for Heidelberg Pharma AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG ROE % Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.12 -125.94 -267.02 -53.73 -35.08

Heidelberg Pharma AG Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.40 -67.63 0.88 -35.77 -38.06

Competitive Comparison of Heidelberg Pharma AG's ROE %

For the Biotechnology subindustry, Heidelberg Pharma AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's ROE % distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's ROE % falls into.



Heidelberg Pharma AG ROE % Calculation

Heidelberg Pharma AG's annualized ROE % for the fiscal year that ended in Nov. 2023 is calculated as

ROE %=Net Income (A: Nov. 2023 )/( (Total Stockholders Equity (A: Nov. 2022 )+Total Stockholders Equity (A: Nov. 2023 ))/ count )
=-20.346/( (66.644+49.34)/ 2 )
=-20.346/57.992
=-35.08 %

Heidelberg Pharma AG's annualized ROE % for the quarter that ended in Feb. 2024 is calculated as

ROE %=Net Income (Q: Feb. 2024 )/( (Total Stockholders Equity (Q: Nov. 2023 )+Total Stockholders Equity (Q: Feb. 2024 ))/ count )
=-17.976/( (49.34+45.114)/ 2 )
=-17.976/47.227
=-38.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2024) net income data. ROE % is displayed in the 30-year financial page.


Heidelberg Pharma AG  (XTER:HPHA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-17.976/47.227
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-17.976 / 5.068)*(5.068 / 66.0095)*(66.0095 / 47.227)
=Net Margin %*Asset Turnover*Equity Multiplier
=-354.7 %*0.0768*1.3977
=ROA %*Equity Multiplier
=-27.24 %*1.3977
=-38.06 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-17.976/47.227
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-17.976 / -17.78) * (-17.78 / -21.2) * (-21.2 / 5.068) * (5.068 / 66.0095) * (66.0095 / 47.227)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.011 * 0.8387 * -418.31 % * 0.0768 * 1.3977
=-38.06 %

Note: The net income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Heidelberg Pharma AG ROE % Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG (XTER:HPHA) Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines